Aardvark Therapeutics (AARD) vs Rockwell Medical (RMTI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rockwell Medical (RMTI) has outperformed Aardvark Therapeutics (AARD) over the past year, losing 34.6% versus a loss of 90.2%. Rockwell Medical is the larger company by market cap ($23.1 million vs $20.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AARD | RMTI |
|---|---|---|
| Share price | $0.9226 | $5.82 |
| Market cap | $20.20M | $23.12M |
| 1-day change | -7.74% | -7.03% |
| YTD return | -92.97% | -29.88% |
| 1-year return | -90.15% | -34.61% |
| 5-year return | — | -87.98% |
| Forward P/E | — | 83.14 |
| EPS (TTM) | $-3.33 | $-1.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $69.26M |
| Revenue growth (YoY) | — | -31.76% |
| Net income (latest FY) | $-57.59M | $-5.31M |
| Gross margin | — | 16.89% |
| Operating margin | — | -6.77% |
| Net margin | — | -7.67% |
| 52-week high | $16.60 | $12.90 |
| 52-week low | $0.90 | $4.89 |
| Distance from 52-week high | -94.44% | -54.88% |
| Analyst consensus | buy | none |
| Avg. price target upside | +1104.21% | +243.64% |
| Average volume | 643.53K | 25.91K |
| Shares outstanding | 21.89M | 3.97M |
| Employees | 28 | 157 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RMTI has outperformed AARD by 55.5 percentage points over the past year.
About Aardvark Therapeutics
AARD stock →Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Rockwell Medical
RMTI stock →Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers.
Health Care · Biotechnology: Pharmaceutical Preparations · 157 employees
AARD vs RMTI FAQ
Which is bigger, Aardvark Therapeutics or Rockwell Medical?
Rockwell Medical (RMTI) is larger, with a market capitalization of $23.12M compared with $20.20M for Aardvark Therapeutics (AARD).
Which stock has performed better over the past year, AARD or RMTI?
RMTI returned -34.61% over the past 12 months, compared with -90.15% for AARD (price return, excluding dividends). Past performance does not predict future results.
Are Aardvark Therapeutics and Rockwell Medical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.